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Improvements	in	immunosuppression	have	modified	short-	term	survival	of	deceased-	
donor	allografts,	but	not	their	rate	of	 long-	term	failure.	Mismatches	between	donor	
and	recipient	HLA	play	an	important	role	in	the	acute	and	chronic	allogeneic	immune	
response	against	the	graft.	Perfect	matching	at	clinically	relevant	HLA	loci	does	not	
obviate	the	need	for	immunosuppression,	suggesting	that	additional	genetic	variation	
plays	a	critical	role	in	both	short-	and	long-	term	graft	outcomes.	By	combining	patient	
data	and	samples	from	supranational	cohorts	across	the	United	Kingdom	and	European	
Union,	we	performed	 the	 first	 large-	scale	genome-	wide	association	 study	analyzing	
both	donor	and	recipient	DNA	in	2094	complete	renal	transplant-	pairs	with	replication	
in	5866	complete	pairs.	We	studied	deceased-	donor	grafts	allocated	on	the	basis	of	
preferential	HLA	matching,	which	provided	some	control	for	HLA	genetic	effects.	No	
strong	donor	or	recipient	genetic	effects	contributing	to	long-	or	short-	term	allograft	
survival	were	 found	outside	the	HLA	region.	We	discuss	 the	 implications	 for	 future	
research	and	clinical	application.
K E Y W O R D S
basic	(laboratory)	research/science,	genomics,	graft	survival,	kidney	transplantation/nephrology,	
rejection,	translational	research/science
1  | INTRODUCTION
Kidney	 transplantation	 is	 a	 highly	 successful	 treatment	 for	 end-	
stage	 renal	 failure,	with	 significant	 benefits	 for	 recipients	 both	 in	
survival	and	quality	of	 life.	Early	outcomes	have	steadily	 improved	
over	 the	 last	10	years,1	with	 risk-	adjusted	and	death-	censored,	1-	
year	 renal	 graft	 survival	 rates	 of	 94%	 and	 97%	 for	 deceased	 and	
living donor transplants, respectively.2	However,	both	late	allograft	
loss	and	increased	mortality	among	transplant	recipients	remain	key	
challenges	 for	 the	 transplant	 community.	 There	 are	 a	 wide	 num-
ber	 of	 factors	 that	 are	 known	 to	 influence	 long-	term	 transplant	
outcome,	 including	 donor	 factors	 such	 as	 age	 and	 comorbidity,	
recipient	 factors	 such	 as	 comorbidity	 and	 response	 to	 immuno-
suppression,	as	well	as	allograft	 ischemic	 time,	 the	degree	of	HLA	
mismatch,	 and	 the	 development	 of	 donor-	specific	 antibodies.3-5 
However,	 a	 comprehensive	 understanding	 of	 the	 pathophysiology	
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of	graft	failure	has	remained	elusive,	with	the	observed	variation	in	
patient	outcomes	still	inadequately	explained	by	our	current	under-
standing	of	 risk	 factors.	An	 improved	understanding	of	 the	deter-
minants	of	 transplantation	outcome	would	allow	the	development	
of	truly	personalized	approaches	to	the	management	of	transplant	 
recipients.
The	 importance	of	 genetic	 factors	 in	 transplantation	has	been	
clear	 since	 the	 inception	 of	 the	 technique,	with	 the	 first	 success-
ful	 kidney	 transplant	 having	 been	 performed	 between	 identical	
twins	 in	1954.	Renal	 transplantation	between	 identical	 twins	con-
tinues	 to	 show	 excellent	 long-	term	 outcomes,6,7	 and	HLA	match-
ing	has	a	 large	 impact	on	graft	survival	even	 in	the	modern	era	of	
immunosuppression.8
HLA	genes	are	highly	polymorphic,	 and	demonstrate	 the	 impor-
tance	of	genetic	variation	 in	donor-	recipient	pairing	that	 impacts	on	
long-	term	 outcomes.	 However,	 over	 recent	 decades,	 our	 ability	 to	
assay	human	genetic	variation	beyond	the	HLA	region	has	increased	
considerably.
A	number	of	studies	have	been	published	over	recent	years	ex-
ploring	 the	 association	 between	 genotypes	 of	 interest	 and	 renal	
transplant outcomes.9,10	A	 large	proportion	of	 these	studies	have	
concentrated	 on	 immune-	related	 genes,	 based	 on	 the	 hypoth-
esis	 that	 the	 risk	 of	 acute	 rejection	 or	 late	 allograft	 loss	may	 be	
modulated	by	genetic	variation	 in	 the	 immune	 response.	As	sum-
marized	 in	 Table	 S1,	 associations	 have	 been	 described	 between	
various	 transplant	 phenotypes	 and	 single	 nucleotide	 polymor-
phisms	 (SNPs)	 in	 a	 number	 of	 genes	 including	 those	 encoding	
tumor	necrosis	 factor-	α,	 interleukins-	1,	 -	6,	 and	 -	10,	 and	 interfer-
on-	γ.	 Of	 note,	many	 of	 these	 studies	 have	 reported	 inconsistent	
findings.	For	example,	analysis	of	DNA	from	donor-	recipient	pairs	
in	the	Collaborative	Transplant	Study	failed	to	replicate	an	earlier	
finding	that	particular	combinations	of	C3	genotypes	in	the	donor	
and	 recipient	 were	 associated	 with	 reduced	 graft	 survival.11,12 
While	 some	 of	 this	 discrepancy	 might	 be	 explained	 by	 method-
ological	 or	 populational	 differences	 between	 these	 studies,	 it	 is	
difficult	 to	draw	firm	conclusions	about	 the	 role	of	 these	genetic	 
variations.13
More	recently,	attention	has	also	focused	on	non-	immune-	related	
genetic	 risk	variants.	Donor	genetic	variation	 in	CAV1	 (caveolin-	1),14 
APOL1	(apolipoprotein-	L1),15,16 or ABCB1	(ATP-	binding	cassette,	sub-
family-	B,	 member-	1,	 expressed	 in	 the	 kidney)	 genes	 17,18	 has	 been	
reported	 to	 be	 associated	with	 increased	 risk	 of	 allograft	 failure	 or	
poorer recipient survival. Recipient genetic variation effects on graft 
and	patient	survival	have	only	been	reported	in	1	cohort	for	CAV1.14 
In	addition	to	effects	of	donor	genetic	variants,	it	might	be	expected	
that	recipient	genotypes	in	other	pharmacometabolic	pathways	might	
also	 impact	on	 transplant	outcomes	 such	 as	 increased	 risk	of	 acute	
rejection.19
In	 general,	 candidate	 gene	 studies	 in	 renal	 transplantation	 have	
so	 far	 failed	 to	 provide	 consistent	 and	 reproducible	 results.	 Some	
of	 the	 reasons	 for	 this	may	 include	 small	 sample	 sizes,	variations	 in	
genotyping	 methodology	 and	 strategy,	 and,	 perhaps	 most	 impor-
tantly,	a	 lack	of	consistency	 in	clinical	phenotyping.20	Genome-	wide	
association	studies	(GWAS)	have	contributed	greatly	to	an	increased	
understanding	of	complex	common	conditions	such	as	inflammatory	
bowel	disease,	hypertension,	type	2	diabetes,	and	schizophrenia.21	A	
small	number	of	GWAS	have	been	reported	in	the	field	of	renal	trans-
plantation,	 describing	 SNPs	 associated	 with	 cardiovascular	 adverse	
events	in	recipients	taking	calcineurin	inhibitor	immunosuppression,22 
2	SNPs	associated	with	serum	creatinine	levels	at	5	years	posttrans-
plant,23	 and	a	number	of	SNPs	associated	with	 the	development	of	
new-	onset	diabetes	after	 transplantation.24	Recently,	a	GWAS	using	
pooled	DNA	of	recipient-	only	origin	found	variation	in	2	new	loci	as-
sociated	with	acute	rejection	in	both	univariate	and	multivariate	anal-
ysis.25	However,	 these	 studies	were	underpowered	 for	 discovery	of	
genetic	variants	with	small	effect	sizes.
The	Wellcome	Trust	Case	Control	Consortium	(www.wtccc.org.
uk/ccc3)	has	led	the	deployment	of	GWAS	in	a	wide	range	of	condi-
tions.	As	part	of	WTCCC-	3,	all	renal	transplant	centers	in	the	United	
Kingdom	and	Ireland	formed	the	United	Kingdom	and	Ireland	Renal	
Transplant	 Consortium	 (UKIRTC;	 www.ukirtc.org).	 Collaborative	
initiatives	such	as	these	are	essential	for	the	collection	of	adequate	
sample	 numbers,	 for	 the	 sharing	 of	 expertise,	 standardization	 of	
techniques,	 and	 building	 consensus	 on	 accurate	 phenotyping	 of	
clinical	 data.	 Through	 this	 consortium,	 3936	 samples	 comprising	
2094	 complete	 donor-	recipient	 pairs	 were	 tested	 in	 the	 GWAS	
discovery	phase,	and	an	additional	5866	complete	donor-	recipient	
pairs	 in	the	replication	phase,	making	this	the	 largest	GWAS	con-
ducted to date in renal transplantation outcomes.
2  | METHODS
2.1 | Discovery study participants
The	 large	multicenter	United	Kingdom	and	 Ireland	Renal	Transplant	
Consortium	(www.UKIRTC.org),	coordinated	by	King’s	College	London	
in	 partnership	with	 the	WTCCC-	3	 and	 the	National	 Health	 Service	
Blood	and	Transplant	database	(NHS-	BT),	sourced	all	available	good-	
quality	stored	DNA	samples	and	pre-	existing	GWAS	data	from	both	
recipients	 and	 their	 corresponding	 donors	 from	 all	 renal	 transplan-
tation	 centers	 in	 the	 United	 Kingdom	 and	 the	 Republic	 of	 Ireland	
(listed	in	Table	S2).	The	study	was	approved	by	the	Hammersmith	and	
Queen	Charlotte’s	&	Chelsea	Research	Ethics	Committee	REC	No	08/
H0707/1,	on	October	14,	2009.	Third-party	anonymized	clinical	data	
were	provided	by	NHS-BT	UK.	All	samples	and	anonymized	data	for	
the	replication	cohort	were	provided	by	the	University	of	Heidelberg.
Following	genotyping	and	GWAS	quality	control	 (see	below),	there	
were	2689	unique	recipients,	2204	unique	donors,	and	2094	complete	
donor-	recipient	transplantation	pairs	available	for	analysis.	Figure	1	de-
scribes	the	study	design	and	analysis	steps.	Table	1	provides	additional	in-
formation	for	the	complete	donor-	recipient	pairs	(discrepancies	between	
Figure	1	and	Table	1	are	because	some	recipients	received	more	than	1	
graft,	some	donors	donated	2	kidneys	to	different	recipients,	and	not	all	
recipients	had	matching	donor	GWAS	data	and	vice	versa).	The	samples	
and	 data	 referred	 to	 transplants	 that	 took	 place	 between	 December	
1981	and	December	2007.
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Inclusion	 criteria	 for	 the	 study	 were	 as	 follows:	 (1)	 deceased	
donor	kidney	transplants	only;	(2)	recipient	is	an	adult	(>16	years	old);	 
(3)	 reported	 European	 ancestry	 for	 recipients;	 and	 (4)	 graft	 survival	
time	 >3	months.	 Donor-	recipient	 allocation	 followed	 NHS-	BT	 stan-
dard	UK-	protocols	during	the	study	period.
2.2 | Replication phase participants
A	cohort	of	5866	complete	donor-	recipient	pairs,	with	similar	ethnicity	
to	that	of	the	discovery	study,	were	obtained	from	the	Collaborative	
Transplant	Study	DNA	Biobank	held	at	the	University	of	Heidelberg,	
Germany	(Table	1).
Clinical	 variables,	 datasets,	 and	 analysis	 are	 described	 in	
Supplementary	Methods.
2.3 | Discovery phase genotyping and analysis
A	whole	genome	amplification	step	was	undertaken	(Source	BioScience,	
Nottingham)	 for	samples	containing	5-	40	μL	of	DNA	 (n	=	990	samples).	
Samples	were	assayed	via	Illumina	670	Quad	Custom	GWAS	chips,	and	
subjected	to	standard	postgenotyping	quality	control	procedures	before	
being	imputed	to	the	1000-	genomes	reference	dataset.	Imputation	of	HLA	
alleles	from	SNP	genotype	data	was	undertaken	using	HLA*IMP	software26 
and	compared	to	serologically	typed	alleles.	A	series	of	GWAS	analyses	were	
performed	to	investigate	different	genetic	models	and	the	renal	transplant	
outcomes	of	interest.	Graft	survival	genome-	wide	analyses	were	performed	
(using	Cox	proportional	 hazards	modeling)	 for	 (1)	 donor	SNP	genotype	
main	effects;	(2)	recipient	SNP	genotype	main	effects;	(3)	donor*recipient	
SNP	 genotype	 interaction	 effects	 (1df	 and	 3df	 tests);	 and	 (4)	 CNV-	 
	tag-	SNPs	genotype	mismatch	effects	 (2	different	models).	Acute	 rejec-
tion	 genome-	wide	 analyses	 were	 performed	 (using	 logistic	 regression)	
for	models	(1)-(3).	An	end-	stage	renal	failure	genome-	wide	analysis	was	
performed	(using	logistic	regression)	for	model	(2),	and	to	take	advantage	
of	the	opportunity,	an	intracranial	hemorrhage	genome-	wide	analysis	was	
performed	(using	logistic	regression)	for	model	(1).
2.4 | Replication- phase genotyping and analysis
Replication	DNA	samples	were	received	at	King’s	College	London	and	
sent	to	the	Wellcome	Trust	Sanger	Institute	for	replication	analysis.	A	
F IGURE  1 Analysis	workflow	and	strategy.	Main	input	cohorts,	analysis	methods,	and	sample	sizes	are	indicated.	For	binary	traits,	numbers	
indicate	samples	with/without	the	trait.	For	further	details,	see	Methods	and	Supplementary	Methods.	GWAS,	genome-	wide	association	
studies; WTCCC, Wellcome Trust Case Control Consortium
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replication	panel	of	139	SNPs	(post–quality	control)	was	tested	based	
on	a	 combination	of	 low	P	 value	 (<10−6)	 from	 the	discovery	phase,	
plus	 good	 support	 of	 association	 signals	 from	SNPs	 in	 local	 linkage	
disequilibrium	(LD),	or	on	prior	candidature	from	previous	association	
studies.	SNPs	were	tested	according	to	the	same	model	as	motivated	
their	 inclusion	 in	 the	 replication	 panel	 (for	 example,	 if	 nominated	
based	on	a	low	P	value	for	acute	rejection	in	recipients,	then	that	was	
also	the	test	of	 interest	 in	the	replication	analysis).	Meta-	analysis	of	
discovery	and	 replication	 results	was	carried	out	using	 inverse	vari-
ance	meta-	analysis.27
For	 further	 details	 see	Figure	1	 and	 the	Methods	 section	 in	 the	
Supplementary Material.
2.5 | Role of the funding source
The	funding	sources	did	not	participate	in	the	study	design,	collection,	
analysis	or	interpretation	of	the	data,	nor	did	they	have	a	role	in	writ-
ing	the	report	or	the	decision	to	submit	for	publication.
3  | RESULTS
3.1 | SNP association analysis
Despite	 the	 large	 size	 of	 our	 study	 (Table	1	 and	 Table	 S2),	
none	 of	 the	 phenotypes	 and	 genetic	 models	 tested	 in	 the	
TABLE  1  Indicative	renal	transplant	demographics	from	WTCCC3	and	the	validation	cohort.	For	consistency,	numbers	refer	to	transplants	
where	both	donors	and	recipients	passed	QC	(“complete”	donor-	recipient	pairs)
WTCCC3 (post QC) % Replication cohort %
Total	transplants	where	both	donors	and	
recipients passed QC
2094 100 5866 100
Total	unique	donors	with	a	paired	recipient 1850 100 5027 100
Total	unique	recipients	with	a	paired	donor 2086 100 5866 100
Mean donor age ± SD 43	±	15.4 43	±	16.7
Mean recipient age ± SD 45	±	13.3 48	±	13.6
0 previous grafts 1864 89 N/A
1 previous graft 204 9.7 N/A
2 or more previous grafts 26 1.2 N/A
Graft	survival	time	(days-	to-	uncensored-	event,	
25%	quartile)
902 442
Graft	survival	time	(days-	to-	uncensored-	event,	
median)
1866 1769
Graft	survival	time	(days-	to-	uncensored-	event,	
75%	quartile)
3165 3162
0	HLA	mismatches 223 10.7 N/A
1	or	2	Class	I	HLA	mismatches 839 40.1 N/A
1	or	2	Class	II	HLA	mismatches 20 0.96 N/A
1	or	2	mixed	Class	I/II	HLA	mismatches 124 5.9 N/A
3	to	5	HLA	mismatches 612 29.2 N/A
6	HLA	mismatches 8 0.4 N/A
N/A	HLA	mismatches 268 12.8 N/A
Graft	survival:	total	uncensored 495 23.6 2951 50.3
Graft	survival:	total	censored 1599 76.4 2915 49.7
Total	double-	kidney	transplants 3 0.14 N/A
Total	en	bloc	kidney	transplants 1 0.05 N/A
Total	kidney+pancreas	transplants 16 0.76 N/A
Total	kidney-	only	transplants 2074 99.0 N/A
Total	rejections	(first	3	mo) 259 12.4 N/A
Total	no	rejections	(first	3	mo) 915 43.7 N/A
N/A	rejections	(first	3	mo) 920 43.9 N/A
Total	rejections	(3-	12	mo) 221 10.6 575 9.8
Total	no	rejections	(3-	12	mo) 946 45.2 2573 43.9
N/A	rejections	(3-	12	mo) 927 44.3 2718 46.3
N/A,	data	not	available;	QC,	quality	control;	WTCCC3,	Wellcome	Trust	Case	Control	Consortium-	3.
6  |     HERNANDEZ- FUENTES ET Al.
discovery	 phase	 produced	 any	 LD-	supported	 single-	SNP	 re-
sults	of	 genome-	wide	 significance	 (P	≤	5	×	10−8).	We	also	per-
formed	a	partitioned	heritability	analysis	via	stratified	LD	score	
regression,28	which	 failed	 to	 reveal	 any	 significant	enrichment	
of	heritability	 in	genomic	 regions	marking	 tissue-	or	cell-	type-	
specific	activity	(Figure	2).
We	pursued	a	second	“replication”	phase	in	the	hope	that	the	most	
significant	SNPs	would	be	enriched	for	true	association	signals.	One	
F IGURE  2 Partitioned	heritability	analysis	of	graft	survival	GWAS	results.	X-	axis	indicates	–log10	(P	value)	for	a	test	for	heritability	
enrichment	within	10	cell/tissue-	type	categories	of	genomic	annotations,	marking	tissue-	or	cell-	type-	specific	activity.	Dotted	lines	indicate	
Bonferroni	significance	level.	(A)	Death	treated	as	a	censored	event;	(B)	death	treated	as	a	failure	event.	CNS,	central	nervous	system
A
B
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hundred	 thirty-	nine	 SNPs	 (post–quality	 control)	were	 tested,	 based	
either	on	a	low	P	value	from	the	discovery	phase	plus	LD	support	or	
on	prior	candidature	from	previous	association	studies.	In	general,	the	
distribution	of	replication	P	values	for	all	the	tests	did	not	depart	ap-
preciably	from	that	expected	under	a	global	null	hypothesis	(Table	S3).	
There	was	some	enrichment	for	low	P	values	in	the	recipient	genotype	
main	effect	tests	for	acute	rejection	in	the	12	months	following	trans-
plantation.	However,	the	P	values	from	meta-	analysis	(across	both	dis-
covery	and	replication	phases)	did	not	reach	genome-	wide	significance	
(P	≤	5	×	10−8).	The	single	SNP	with	strongest	evidence	for	association	
was	rs2289887	(Figure	S1	and	Table	S4),	which	had	consistent	effects	
in	both	cohorts	but	a	meta-	analysis	P value of only 0.00011, indicating 
that	further	studies	are	needed	to	establish	the	validity	of	this	signal.
We	collated	all	previously	published	association	signals	 for	early	
graft	rejection	and	long-	term	allograft	survival	and	none	of	these	rep-
licated	in	our	study	(Table	S1).
3.2 | HLA mismatch analysis
We	took	advantage	of	recorded	serological	 information	to	check	for	
known	associations	with	donor-	recipient	mismatch	levels	and	to	com-
pare	 recorded	 information	with	 imputed	mismatches	based	on	SNP	
genotype	 information	 (Figure	3).	 As	 expected	 for	 deceased	 donor	
transplants,	the	number	of	non-	zero	mismatch	transplants	in	our	data	
was	low,	reducing	our	power	to	detect	associations.	Nevertheless,	we	
confirmed	 significant	 associations	 with	 HLA-	A	 (P	=	.022)	 and	 HLA-	
DRB	(P	=	.00049)	mismatches	using	the	recorded	data.
On	the	other	hand,	the	imputed	mismatch	results	did	not	reproduce	
the	expected	associations.	We	attribute	 this	 to	2	 factors:	 (1)	 the	 true	
mismatch	=	2	frequency	was	low,	due	to	donor	selection;	(2)	as	with	any	
statistical	noise,	the	imputation	inaccuracy	tended	to	act	with	dispropor-
tionate	effect	in	the	extremes	of	the	distribution	(here,	the	mismatch	=	2	
group),	resulting	in	higher	relative	errors	in	that	group.	Thus,	although	the	
overall	imputation	accuracy	was	high	(Tables	S5	and	S6),	the	rate	of	false	
positives	was	 disproportionately	 high	 in	 the	mismatch	=	2	 categories,	
swamping	our	ability	to	detect	the	true	association	signals	(Table	S7).
4  | DISCUSSION
In	this	article,	we	report	the	results	of	the	first	large-	scale	GWAS	in	
renal	transplantation.	Despite	our	considerable	sample	size,	we	did	not	
replicate any proposed findings from previous candidate gene studies 
nor	did	we	discover	any	convincing	new	variants	in	our	own	analyses.	
There	are	a	number	of	plausible	reasons	that	may	explain	this.
Firstly,	although	this	was	a	study	involving	thousands	of	individu-
als,	by	GWAS	standards	it	was	at	the	lower	end	of	the	range	of	sample	
sizes	that	have	been	employed	for	other	human	traits.29,30	A	decade	of	
GWAS	across	multiple	complex	traits	has	shown	that	single	effect	sizes	
for	any	1	causal	variant	are	typically	low,	and	thus	for	some	traits	even	
bigger	 sample	 sizes	 than	ours	are	needed	 to	discover	 them.	For	ex-
ample,	the	first	robustly	associated	locus	for	schizophrenia	was	found	
in	a	discovery	GWAS	cohort	of	3322	cases	and	3587	controls.31	The	
number	of	reliably	associated	signals	for	schizophrenia	has	now	grown	
F IGURE  3 Kaplan-	Meier	plots	of	graft	survival	by	number	of	mismatches	by	serological	typing	(A,	B,	and	C),	imputed	2-	digit	resolution	(D,	E,	
and	F),	and	imputed	4-	digit	resolution	(G,	H,	and	I).	P	values	were	obtained	from	likelihood	ratio	tests	on	Cox	proportional	hazards	models
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to	108,	providing	new	biological	 insights	 into	the	disease,	 thanks	to	
a	meta-	analysis	that	involved	40	000	cases	and	113	000	controls.32
Secondly,	part	of	our	study	sought	to	look	for	recipient-	donor	ge-
netic	interactions.	Interaction	effects	require	even	larger	sample	sizes	
to	 be	 reliably	 discovered.	With	 a	 few	 notable	 exceptions,33	 GWAS	
studies	on	other	traits	have	been	unsuccessful	in	discovering	reliable	
interaction effects.
Thirdly,	 and	 perhaps	 most	 importantly,	 the	 transplantation	 out-
comes	we	considered	were	relatively	crude	measures	obtained	retro-
spectively from national registry data, collected over many years for 
reasons	other	 than	 for	 acting	 as	 endpoints	 in	 a	 genome-	wide	 asso-
ciation	 study.	Our	outcomes	were	 therefore	heterogeneous,	 subject	
to	missingness,	and	subject	to	environmental	factors	that	likely	weak-
ened	 the	genetic	 signals.	Graft	 survival	 time	 is	expected	 to	be	 sub-
ject	to	a	range	of	factors	including	graft	quality,	drug	regimen,	patient	
compliance,	 changes	 in	 standard-	of-	care	 over	 time,	 between-	center	
differences,	 and	 underlying	 biological	 causes	 of	 renal	 dysfunction.	
Additionally,	a	 substantial	proportion	of	 the	survival	 time	data	were	
right-	censored	 (60.5%-	76.4%,	depending	on	model	being	 fitted),	 re-
ducing	the	power	for	this	endpoint.
Acute	graft	rejection	is	also	a	heterogeneous	phenotype	arising	from	
various	 immune	and	nonimmune	biological	 causes.	 Furthermore,	 this	
phenotype	was	derived	from	a	field	that	in	many	records	was	left	blank,	
resulting	in	a	high	degree	of	missingness	(56.7%-	58.3%,	depending	on	
model	being	fitted).	The	high	missingness	rate	reduced	the	power	of	our	
study,	and	nonrandom	missingness	would	complicate	the	interpretation	
of	any	positive	association	signals	we	might	have	found	(although	we	
note	 the	nonrandom	missingness	bias	would	need	to	be	 the	same	 in	
both	the	discovery	and	replication	cohorts	for	a	signal	to	be	replicated).
Batch	effects	are	also	a	concern.	Both	the	discovery	and	replica-
tion	data	were	obtained	 from	multiple	 different	 collection	points	 in	
different	countries	over	many	years,	and	thus	our	phenotypes	may	be	
subject	to	batch	effects,	for	example,	arising	from	different	treatment	
protocols	 over	 time	 and	 space.	Genetic	 data	 can	 also	be	 subject	 to	
batch	effects,	for	example,	arising	from	differences	in	sample	collec-
tion	protocols	and	unknown	differences	 in	population	structure.	We	
applied	both	covariate	selection	and	genetically	derived	principal	com-
ponent	axes	to	try	to	mitigate	such	effects.	We	also	note	that,	as	with	
nonrandom	missingness,	the	batch	effect	structure	would	need	to	be	
the	 same	 in	both	 the	discovery	 and	 replication	 cohorts	 in	order	 for	
false-	positive	 association	 signals	 to	 be	 replicated.	 Nevertheless,	 to-
gether	these	extraneous	factors	may	well	have	increased	the	noise	in	
our	data,	and	so	reduced	(and	made	less	detectible)	the	genetic	effects	
in our data.
HLA	imputation	from	chip-	based	genetic	data	might	in	time	be	of	
value	as	an	adjunct	to	serological	typing.	However,	our	investigations	
found	that	the	additional	noise	introduced	by	imputation	uncertainty	
prevented	the	imputed	data	from	picking	up	the	well-	known	mismatch	
signals	 at	HLA-	A	 and	HLA-	DRB.	This	 suggests	 that	 the	 accuracy	of	
HLA	imputation	will	need	to	be	improved	before	it	can	be	used	reliably	
as an alternative to serotyping.
In	contrast,	our	serological	data	successfully	detected	the	HLA-	A	
and	HLA-	DRB	mismatch	signals,	despite	the	reduced	power	to	do	so	
resulting	from	HLA-	matching	of	deceased	donor	allografts.	This	indi-
cates	that,	despite	the	various	shortcomings	of	our	study,	strong	HLA	
signals	were	detectable	in	our	data.	The	implication	therefore,	at	least	
as	far	as	our	primary	graft	survival	endpoint	is	concerned,	is	that	sig-
nals	outside	the	HLA	region	are	weaker	than	those	already	established	
in	the	HLA	region.	We	therefore	anticipate	that	genetic	effects	outside	
of	the	HLA	region	are	more	likely	to	be	of	value	in	elucidating	biologi-
cal	pathways	than	in	direct	clinical	prediction.
We	explored	this	last	point	further	via	formal	power	calculations.	
These	 indicated	 that	we	were	well	 powered	 to	detect	 any	main	 ef-
fect	 graft	 survival	 association	 signals	 involving	 causal	 SNPs	 with	
allelic	 hazard	 ratios	 in	 the	 range	 1.4-	1.9	 (log-	additive	 risk	 model,	
alpha	=	5	×	10−8,	 power	=	0.8,	 minor	 allele	 frequency>0.05),	 and	 to	
detect	main-	effect	acute	rejection	association	signals	with	allelic	odds	
ratios	in	the	range	1.7-	2.9.	We	emphasize	that	these	effect	sizes	are	
applicable	to	the	traits	investigated	in	this	study,	but	that	larger	effects	
might	be	found	in	future	studies	under	more	precise	phenotyping.
In	summary,	while	our	study	was	able	to	replicate	known	mismatch	
signals	in	the	HLA	region,	we	failed	to	find	convincing	association	sig-
nals	 outside	 of	 the	HLA	 region.	 Both	 phenotype	 heterogeneity	 and	
sample	 size	may	have	 contributed	 to	 this	 result.	 Looking	 ahead,	we	
note	that	the	general	lessons	from	GWAS	applied	to	multiple	human	
traits	 over	 more	 than	 a	 decade	 have	 brought	 home	 3	 clear	 mes-
sages.29,30	The	 first	 is	 that	all	 complex	 traits	contain	a	genetic	com-
ponent,	and	harbor	a	large	number	of	causal	variants	throughout	the	
genome.	The	second	is	that	larger	GWAS	studies,	often	obtained	via	
meta-	analysis	with	previous	studies,	inevitably	succeed	in	discovering	
some	portion	of	these	causal	variants.	The	third	is	that	when	a	large	
enough	portion	of	these	variants	is	discovered,	new	insights	into	the	
biology	 of	 the	 trait	 are	 gained.	With	 these	 points	 in	mind,	we	 look	
forward	to	an	international	consortium	(iGeneTrain34),	which	has	been	
formed	to	share	and	meta-	analyze	genetic	and	phenotypic	data	from	
most	major	transplant	cohorts	worldwide.	We	also	look	forward	to	ef-
forts	to	collect	more	detailed	phenotypes	of	relevance	to	transplant	
failure,	which	should	provide	greater	genetic	resolution.	The	data	pro-
vided	by	our	study	form	a	foundation	for	ongoing	efforts	seeking	to	
uncover	the	biology	and	improve	the	prospects	for	renal	transplanta-
tion outcomes.
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